The Melanoma Research Foundation ( MRF ) has charted a comprehensive assessment of
the current state of melanoma research and care. Intensive discussions among members of …

PLX-4032 is a small-molecule, orally available B-Raf kinase inhibitor being developed by
Plexxikon Inc and Hoffman-La Roche Ltd for the treatment of cancers harboring activating …

BACKGROUND The development of brain metastases is common for systemic treatment
failure in patients with melanoma and has been associated with a poor prognosis. Recent …

BRAF inhibitor (BRAFi) therapy for melanoma patients harboring the V600E mutation is
initially highly effective, but almost all patients relapse within a few months. Understanding the …

Novel anti-cancer treatments use knowledge about the underlying biology of the tumor to
find suitable molecular targets. The recent years have seen great advances in understanding …

Melanoma is the most aggressive form of skin cancer and until recently, it was extremely
resistant to radio-, immuno-, and chemotherapy. Despite the latest success of BRAF V600E-…

… Smalley, PhD, and Nam D. Tran, MD, PhD … No significant relationships exist between
Drs Smalley and Tran and the companies/organizations whose products or services may be …

Background The development of brain metastases is common in patients with melanoma
and is associated with a poor prognosis. Treating patients with melanoma brain metastases (…

Anthrax lethal toxin (LeTx) shows potent mitogen-activated protein kinase pathway inhibition
and apoptosis in melanoma cells that harbor the activating V600E B-RAF mutation. LeTx is …

Phosphorylation acts as a molecular switch for many regulatory events in signaling pathways
that drive cell division, proliferation, and apoptosis. Because of the critical nature of these …